Treatment with curative intention for prostate cancer in Norway in 1998 and 2001;Kurativ behandling av prostatakreft i Norge i 1998 og 2001

Tidsskrift for den Norske Laegeforening

Volumn 126, Issue 7, 2006, Pages 912-916

  Kvåle, Rune ^a   Skarre, Elin ^b   Tønne, Andreas ^b   Kyrdalen, Anne E ^c   Norstein, Jarle ^c   Angelsen, Anders ^d   Wahlqvist, Rolf ^e   Fosså, Sophie D ^f  

^a Kreftregisteret   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c St Olavs Hospital ^*  (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e AKER UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CONTROLLED STUDY; HUMAN; MALE; NORWAY; PROSTATE CANCER; PROSTATECTOMY; ADENOCARCINOMA; CLINICAL PRACTICE; MIDDLE AGED; PROSTATE TUMOR; RADIATION DOSE; REGISTER; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; HUMANS; MALE; MIDDLE AGED; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; REGISTRIES; TREATMENT OUTCOME;

EID: 33645637604     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kreft i Norge 2003. Oslo: Kreftregisteret, Institutt for populasjonsbasert kreftforskning, 2005.
2. Alibhai SM, Klotz LH. A systematic review of randomized trials in localized prostate cancer. Can J Urol 2004; 11: 2110-7.
3. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51.
4. Egevad L, Granfors T, Karlberg L et al. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002; 89: 538-42.
5. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
6. Pollack A, Zagars GK, Starkschall G et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097-105.
7. Khatami A, Damber JE, Lodding P et al. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy? A case control study. Scand J Urol Nephrol 2003; 37: 213-7.
8. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005; 47: 16-21.
9. Bakken AM, Øgreid P, Iversen J et al. Normalvevstoksisitet ved strålebehandling av lokalisert prostatacancer. Tidsskr Nor Lægeforen 1999; 119: 2017-21.
10. Vaage S. Radical treatment of organ-localized and locally advanced prostate cancer in Norway - an overview. Scand J Urol Nephrol Suppl 2003; (115): 11-5.
11. Stene JB, Angelsen A. Postoperativ morbiditet og livskvalitet etter radikal retropubisk prostatektomi. Tidsskr Nor Lægeforen 2003; 123: 1657-9.
12. Lilleby W, Fosså SD, Wæhre HR et al. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 735-43.
13. Karlsdottir A, Johannessen DC, Muren LP et al. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 2004; 71: 43-53.
14. Fowler FJ jr., McNaughton Collins M, Albertsen FC et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000; 283: 3217-22.
15. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-84.
16. Potosky AL, Davis WW, Hoffman RM et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2004; 96: 1358-67.
17. Kupelian PA, Elshaikh M, Reddy CA et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol2002; 20: 3376-85.
18. Gjengsto P, Eide J, Frugard J et al. The potentially curable prostate cancer patient and the pathways leading to diagnosis and treatment. Scand J Urol Nephrol 2004; 38: 15-8.
19. www.nice.org.uk/pdf/Urological_Manual.pdf (25.4.2005).
20. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med 2002; 137: 511-20.
21. Begg CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346: 1138-44.
22. Urbach DR, Baxter NN. Does it matter what a hospital is «high volume» for? Specificity of hospital volume-outcome associations for surgical procedures: Analysis of administrative data. BMJ 2004; 328: 737-40.